See more : Constellation Acquisition Corp I (CSTA-UN) Income Statement Analysis – Financial Results
Complete financial analysis of UroGen Pharma Ltd. (URGN) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of UroGen Pharma Ltd., a leading company in the Biotechnology industry within the Healthcare sector.
- Cineverse Corp. (IQ50.F) Income Statement Analysis – Financial Results
- WuXi Biologics (Cayman) Inc. (2269.HK) Income Statement Analysis – Financial Results
- China Overseas Property Holdings Limited (2669.HK) Income Statement Analysis – Financial Results
- SLR Investment Corp. (SLRC) Income Statement Analysis – Financial Results
- DNAPrint Genomics, Inc. (DNAG) Income Statement Analysis – Financial Results
UroGen Pharma Ltd. (URGN)
About UroGen Pharma Ltd.
UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization novel solutions for specialty cancers and urothelial diseases. It offers RTGel, a polymeric biocompatible and reverse thermal gelation hydrogel to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution. The company's lead product candidate is UGN-102, which is in Phase III clinical trials for the treatment of several forms of non-muscle invasive urothelial cancer that include low-grade upper tract urothelial carcinoma and low-grade non-muscle invasive bladder cancer. It is also developing UGN-301 for the treatment of high-grade non-muscle invasive bladder cancer. The company has a license agreement with Allergan Pharmaceuticals International Limited for developing and commercializing pharmaceutical products that contain RTGel and clostridial toxins; Agenus Inc. to develop, make, use, sell, import, and commercialize products of Agenus for the treatment of cancers of the urinary tract via intravesical delivery; and strategic research collaboration with MD Anderson to advance investigational treatment for high-grade bladder cancer. UroGen Pharma Ltd. was incorporated in 2004 and is based in Princeton, New Jersey.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 82.71M | 64.36M | 48.04M | 11.80M | 18.00K | 1.13M | 8.16M | 17.53M | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 9.36M | 7.65M | 5.16M | 1.01M | 0.00 | 1.80M | 600.00K | 28.00K | 113.00K | 0.00 | 0.00 |
| Gross Profit | 73.35M | 56.70M | 42.89M | 10.79M | 18.00K | -675.00K | 7.56M | 17.50M | -113.00K | 0.00 | 0.00 |
| Gross Profit Ratio | 88.68% | 88.11% | 89.27% | 91.45% | 100.00% | -59.84% | 92.65% | 99.84% | 0.00% | 0.00% | 0.00% |
| Research & Development | 45.61M | 52.91M | 47.64M | 47.31M | 49.30M | 36.93M | 18.70M | 10.29M | 10.52M | 4.01M | 2.33M |
| General & Administrative | 0.00 | 0.00 | 0.00 | 0.00 | 60.20M | 39.57M | 8.81M | 6.42M | 1.90M | 890.00K | 1.06M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 93.27M | 82.84M | 87.54M | 90.22M | 60.20M | 39.57M | 8.81M | 6.42M | 1.90M | 890.00K | 1.06M |
| Other Expenses | 0.00 | 72.00K | 0.00 | 0.00 | -284.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 138.89M | 135.74M | 135.18M | 137.53M | 109.50M | 76.51M | 27.51M | 16.70M | 12.41M | 4.36M | 3.39M |
| Cost & Expenses | 148.25M | 143.40M | 140.33M | 138.54M | 109.50M | 78.31M | 28.11M | 16.73M | 12.41M | 4.36M | 3.39M |
| Interest Income | 2.64M | 1.01M | 212.00K | 1.63M | 4.62M | 1.87M | 0.00 | 1.00K | 0.00 | 120.00K | 83.00K |
| Interest Expense | 14.72M | 8.44M | 17.44M | 357.00K | 284.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 1.71M | 1.82M | 1.77M | 2.04M | 1.32M | 417.00K | 207.00K | 213.00K | 113.00K | 30.00K | 18.00K |
| EBITDA | -63.83M | -78.03M | -90.15M | -122.71M | -108.15M | -77.18M | -19.74M | 1.01M | -12.30M | -4.34M | -3.37M |
| EBITDA Ratio | -77.17% | -121.25% | -156.12% | -1,074.15% | -600,855.56% | -6,842.20% | -244.55% | 5.77% | 0.00% | 0.00% | 0.00% |
| Operating Income | -65.54M | -79.04M | -92.29M | -126.74M | -109.48M | -77.18M | -19.95M | 798.00K | -12.41M | -4.37M | -3.39M |
| Operating Income Ratio | -79.23% | -122.82% | -192.11% | -1,074.15% | -608,211.11% | -6,842.20% | -244.55% | 4.55% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | -32.79M | -28.99M | -17.08M | 1.63M | 4.33M | 1.65M | -31.00K | -2.74M | -279.00K | -107.00K | 83.00K |
| Income Before Tax | -98.32M | -108.03M | -109.37M | -125.11M | -105.15M | -75.53M | -19.98M | -1.94M | -12.69M | -4.48M | -3.31M |
| Income Before Tax Ratio | -118.87% | -167.86% | -227.66% | -1,060.34% | -584,144.44% | -6,696.10% | -244.93% | -11.07% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 3.92M | 1.14M | 1.45M | 3.37M | -4.62M | 125.00K | 19.00K | 0.00 | 0.00 | 81.00K | 0.00 |
| Net Income | -102.24M | -109.16M | -110.82M | -128.48M | -100.53M | -75.66M | -20.00M | -1.94M | -12.69M | -4.56M | -3.31M |
| Net Income Ratio | -123.61% | -169.62% | -230.67% | -1,088.94% | -558,500.00% | -6,707.18% | -245.16% | -11.07% | 0.00% | 0.00% | 0.00% |
| EPS | -3.55 | -4.79 | -4.96 | -5.90 | -4.90 | -4.80 | -2.06 | -0.16 | -5.51 | -1.98 | -1.56 |
| EPS Diluted | -3.55 | -4.79 | -4.96 | -5.90 | -4.90 | -4.80 | -2.06 | -0.16 | -5.51 | -1.98 | -1.56 |
| Weighted Avg Shares Out | 28.83M | 22.81M | 22.35M | 21.78M | 20.53M | 15.75M | 9.72M | 11.97M | 2.30M | 2.30M | 2.12M |
| Weighted Avg Shares Out (Dil) | 28.83M | 22.81M | 22.35M | 21.78M | 20.53M | 15.75M | 9.72M | 11.97M | 2.30M | 2.30M | 2.12M |
UroGen Pharma Reports Highest Revenue Quarter and Significant Full Year 2022 Growth and Recent Corporate Developments
UroGen Pharma to Report Fourth Quarter and Full-Year 2022 Financial Results on Thursday, March 16, 2023
UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
UroGen Pharma to Present at Upcoming Investor Conferences
UroGen Pharma to Present at Upcoming Investor Conferences
Investigational Therapy UGN-102 May Be Delivered at Home for the Treatment of Bladder Cancer
Investigational Therapy UGN-102 May Be Delivered at Home for the Treatment of Bladder Cancer
UroGen: Struggling With Revenue And With Cash Runway
Results of the First Post-Commercial Utilization Review of JELMYTO® Provide New Evidence that Reinforces its Efficacy and Safety in Patients with Low-Grade Upper Tract Urothelial Cancer
Results of the First Post-Commercial Utilization Review of JELMYTO® Provide New Evidence that Reinforces its Efficacy and Safety in Patients with Low-Grade Upper Tract Urothelial Cancer
Source: https://incomestatements.info
Category: Stock Reports